Shanghai GeneoDx Biotech Co., Ltd. (GeneoDx) is a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm). GeneoDx is a professi♓onal R&D, production, and sales company of domestic and foreign medical devices and in vitro diagnostic reagents.
Medical diagnosis is one of the key sectors in the development of CNBG's planning. GeneoDx undertakes this part in CNBG. It is also the first company leading CNꦿBG's mixed ownership reform, aiming to promote the rapid development of diagnostic business with institutional innovation. As a unified operation platform company of CNBG's diagnosis sector, GeneoDx integrates functions of R&D, production and trade. By means of independent research and development, technology import, investment, merger and acquisition, it has built a large industrial chain of CNBG's diagnosis sector, and strives to become a leader in the domestic subdivision field. In 2019, mulangren158.completed the first acquisition project of a foreign company within Sinopharm Group, launched the construction of an overseas R&D center, therefore, further accelerated the introduction of global leading technology and broadened the layout overseas.
The 5th China International Import 🥃Expo (hereinafter referred to as "CIIE") will be held at the National Exhibition and Convention Center (Shanghai) 🐟from November 5th to 10th, 2022. In the afternoon of November 5th, Sinopharm CNBG Shanghai GeneoDx Biotech Co., Ltd. (hereinafter referred to as "GeneoDx") signed a strategic cooperation agreement with China Travel Service (Macao) LTD. (hereinafter referred to as "CTS Macao"), a subsidiary of Nam Kwong (Group) Company Limited, to collabrate in medical testing, medical tourism and other fields.
Recently, the 2022 China International Fair for Trade in Services (ღ"CIFTIS") was held in Beijing. Sinopharm Group demonstrated to the public the latest scientific and technological achiev💯ements of SARS-Cov-2-Vaccine, therapeutic drugs, and diagnostic reagents with the "Technology Anti-epidemic China Plan". Among them, as one of the important activities of Sinopharm Group at the CIFTIS, the DNA Methylation Detection Kit for Human ASTN1、DLX1、ITGA4、RXFP3、SOX17、ZNF671 Gene - Cervical Cancer developed by GeneoDx officially debuted in Beijing. Liu Jingzhen, Chairman of the Sinopharm Group, Yang Liu, Deputy Secretary of the Party Committee of Sinopharm Group, Zhu Jingjin, Secretary of the Party Committee of Sinopharm, and other leaders and experts attended the press conference.
On August 4, 2022, the DNA Methylation Detection Kit for Human ASTN1、DLX1、ITGA4、RXFP3、SOX17、ZNF671 Gene -- Cervical Cancer developed by Shanghai GeneoDx Biotech Co., LTD. (hereinafter referred to as GeneoDx) of Sinopharm CNBG has been registered as a medical device issued by the NMPA. This is the first certificate for HPV primary screeni𝕴ng methylation triage for cervical cancer in China.